Abstract: The present disclosure relates to bioactive self-assembling peptides, nanofibers and hydrogels for activating human mast cells. The peptides, nanofibers and hydrogels comprise a self-assembling peptide that mediates self-assembly linked to a MrgX2 agonist peptide; for example, (RADA)4 linked to proadrenomedullin-12 (PAMP-12).
Type:
Grant
Filed:
May 25, 2018
Date of Patent:
June 28, 2022
Assignees:
The Governors of the University of Alberta, National Research Council of Canada
Inventors:
Larry D. Unsworth, Lei Lu, Marianna Kulka
Abstract: Methods and pharmaceutical compositions for treating malaria and immune related disorders are provided. The pharmaceutical compositions include an effective amount a carmaphycin B analog that inhibits immunoproteasome activity in a subject.
Type:
Grant
Filed:
May 15, 2018
Date of Patent:
June 14, 2022
Assignee:
The Regents of the University of California
Inventors:
William Gerwick, Betsaida Bibo Verdugo, Anthony O'Donoghue, Jehad Almaliti
Abstract: Disclosed herein are peptides having activity as cell penetrating peptides. In some embodiments, the peptides can comprise a cell penetrating peptide moiety and beta-hairpin turn creating moiety. In other embodiments, the peptides also comprise a cargo moiety.
Abstract: A modified EGF protein, a production method therefor, and a use thereof are disclosed. The modified EGF protein allows an effective delivery of EGF into the cell and exhibits an enhanced half-life span. A method for producing the modified EGF protein includes culturing conditions where host cell growth phase and protein expression phase employ different temperature conditions. A use of the modified EGF protein is also disclosed.
Abstract: The invention relates to a Myc dominant negative mutant, called Omomyc, for use in medicine and for use in the prevention and/or treatment of cancer. The invention also refers to a fusion protein comprising Omomyc and pharmaceutical composition thereof and their use in medicine and, in particular, for treatment of cancer.
Type:
Grant
Filed:
June 6, 2019
Date of Patent:
May 24, 2022
Assignees:
FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ, ONCOLÓGICA DE VALL HEBRON
Abstract: Provided are a method for promoting the lipolysis and fatty acid oxidative metabolism in mammals or cells derived from mammals, a method for downregulating the fat content and the weight of a mammalian body, as well as a method for increasing the intracellular cAMP concentration, increasing the phosphorylation degree and the activity of the hormone-sensitive esterase HSL, enhancing the transcription activity of PPAR alpha and increasing the activities of enzymes involved in a fatty acid beta oxidation process. By simulating the expression of a protein corresponding to a gene responsible for the phosphorylation of the Fas-associated death domain protein, or treating and acting on mammals or cells derived from mammals with a material that can increase the phosphorylation degree of the Fas-associated death domain protein, said methods increases the phosphorylation of the Fas-associated death domain protein.
Abstract: This disclosure relates to treating internal disc disruption or a connective tissue injury. The treatment involves injecting, or otherwise administering, a therapeutic composition into an animal, such as a human being, in need thereof. The therapeutic composition may contain transforming growth factor beta 1 (TGF-?1) or transforming growth factor beta 2 (TGF-?2), fibroblast growth factor (FGF), and a pharmaceutically acceptable excipient or a secondary agent.
Abstract: The present invention relates to a synthetic compound comprising at least one effector moiety and at least one binder moiety, wherein the effector moiety is associated to the binder moiety, and wherein further the effector moiety comprises a N-formyl methionine peptide which comprises an isoleucine residue (FIG. 1).
Type:
Grant
Filed:
May 24, 2017
Date of Patent:
May 3, 2022
Assignee:
SYNTAB THERAPEUTICS GMBH
Inventors:
Christian Becker, Manuel Brehs, Karine Thewes, Ute Steinbusch, Andre J G Pötgens, Janett Schwarz
Abstract: The present invention relates to a controlled-release CNP agonist having low NPR-C affinity; to pharmaceutical compositions comprising said controlled-release CNP agonist; their use; and to methods of treatment.
Type:
Grant
Filed:
January 5, 2017
Date of Patent:
April 26, 2022
Assignee:
ASCENDIS PHARMA GROWTH DISORDERS A/S
Inventors:
Harald Rau, Ulrich Hersel, Kennett Sprogøe, Frank Faltinger, Thomas Wegge, Felix Cleemann
Abstract: A series of peptides and a peptide-siRNA complex are disclosed, wherein the peptide based complex effectively enhances delivery of siRNA molecules into the cells and release of siRNA in the cell, and improves siRNA mediated gene silencing efficiency of cellular targets. Pharmaceutical compositions that include the complex, as well as a use of the complex in the gene therapy field, are also disclosed.
Type:
Grant
Filed:
January 24, 2020
Date of Patent:
April 19, 2022
Assignees:
Positec Power Tools (Suzhou) Co LTD
Inventors:
Pu Chen, Dafeng Chu, Baoling Chen, Wen Xu, Ran Pan
Abstract: The present disclosure discloses an antimicrobial peptide AS-hepc3(48-56) of Acanthopagrus schlegelii and method thereof. A molecular formula of the antimicrobial peptide AS-hepc3(48-56) is C48H86N24O10S3, and an amino acid sequence of the antimicrobial peptide AS-hepc3(48-56) is SEQ ID NO: 01.
Abstract: Pharmaceutical compositions and methods of their use are provided for reducing inflammation in a subject, blocking leukocyte recruitment, inhibiting tumor metastasis, treating sepsis and preventing/reducing acute kidney injury.
Type:
Grant
Filed:
December 2, 2019
Date of Patent:
March 29, 2022
Assignee:
Arch BioPartners, Inc.
Inventors:
Stephen Mark Robbins, Donna Lorraine Senger, Daniel Abraham Muruve, Saurav Roy Choudhury, Jennifer Joy Rahn, Arthur Wing Sze Lau, Justin MacDonald, Liane Babes, Paul Kubes
Abstract: Methods preventing, ameliorating or treating cytokine storm or inflammatory disease, indications, conditions and syndromes by administration of a therapeutically effective amount of a melanocortin-1 receptor-specific cyclic peptide or pharmaceutically acceptable salt thereof.
Abstract: The present disclosure provides a method of treating a disease associated with a respiratory virus. The method comprises administering an effective amount of a pharmaceutical composition prepared by removing albumin from a solution of a human serum albumin composition and/or comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP), such as a low molecular weight fraction of human serum albumin. The present disclosure also provides a pharmaceutical product as well as a kit comprising DA-DKP.
Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of lipoprotein signal peptidase II (LspA), a key protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.
Type:
Grant
Filed:
March 12, 2020
Date of Patent:
March 22, 2022
Assignee:
Genentech, Inc.
Inventors:
Emily J. Hanan, Georgette Castanedo, Marie Gabrielle Braun, Keira Garland, Peter Andrew Smith, Richard Pastor, Paul Gibbons, Yunxing Cheng, Guosheng Wu, Yuhong Fu, Po-Wai Yuen
Abstract: Provided herein are compositions and methods for treating dry eye or an ocular disease associated with inflammation in a subject in need thereof. The therapeutic compositions comprise an adiponectin peptidomimetic compound, and a pharmaceutically acceptable carrier, and administering a therapeutic agent. Also provided are methods for alleviating one or more symptoms or clinical signs of dry eye or an ocular disease associated with inflammation in a subject in need thereof.
Abstract: A method of treating a sterile inflammatory condition in a subject using an isolated dermcidin peptide or an active fragment thereof of or an active analog thereof is provided. Also provided is a method of inhibiting organ transplantation-associated is chemia/reperfusion and/or organ transplantation-associated inflammation.
Type:
Grant
Filed:
October 21, 2016
Date of Patent:
March 8, 2022
Assignee:
THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH
Abstract: Described herein are membrane permeabilizing peptides and antimicrobial peptides, polynucleotides encoding the peptides, and compositions containing the peptides. Furthermore, described herein are methods for using the peptides, polynucleotides, and compositions for research, diagnosis, and therapy.
Type:
Grant
Filed:
October 25, 2018
Date of Patent:
March 8, 2022
Assignee:
The Administrators of the Tulane Educational Fund
Inventors:
William Charles Wimley, Charles Gannon Starr, William Berkeley Kauffman
Abstract: The present invention relates to insulin analogs, particularly insulin analogs having shortened B chains. The present invention also relates to the crystal structure of insulin from the venom of cone snails and to methods of using the crystal and related structural information to screen for and design insulin analogs that interact with or modulate the insulin receptor. The present invention also relates to therapeutic and prophylactic methods using insulin analogs.
Type:
Grant
Filed:
July 21, 2017
Date of Patent:
February 15, 2022
Assignees:
University of Utah Research Foundation, The Walter and Eliza Hall Institute of Medical Research
Inventors:
John Gerbrandt Tasman Menting, Brian Smith, Danny Hung-Chieh Chou, Helena Safavi-Hemami, Michael Colin Lawrence, Baldomero M. Olivera